My ePortfolio Register   

ASH 2017 /
Axicabtagene ciloleucel for patients with non-hodgkin lymphoma

9th - 12th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.17
Views: 317
Rating:

Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

Dr Neelapu presents, in a press conference at the 2017 ASH annual meeting, data from long term follow up of the ZUMA-1 trial looking at axicabtagene ciloleucel in patients with refractory aggressive non-hodgkin lymphoma.

Watch the interview with Dr Neelapu or read the new story for more. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence